SAN DIEGO, May 12, 2015 /PRNewswire/ -- aTyr Pharma,
Inc. ("aTyr"), today announced the closing of its initial public
offering of 6,164,000 shares of its common stock at an initial
public offering price of $14.00 per share, before underwriting
discounts, including 804,000 shares of common stock issued upon the
exercise in full by the underwriters of their option to purchase
additional shares. aTyr's common stock is listed on The
NASDAQ Global Select Market under the ticker symbol "LIFE."
J.P. Morgan Securities LLC and Citigroup Global
Markets Inc. acted as joint book-running managers for the
offering. BMO Capital Markets Corp. acted as lead manager
and William Blair & Company, L.L.C. acted as
co-manager.
A registration statement relating to these securities was
declared effective by the Securities and Exchange Commission (the
"SEC") on May 6, 2015. The
offering was made only by means of a prospectus. Copies of
the final prospectus relating to the offering may be obtained by
contacting: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood,
New York 11717, by telephone at 866-803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or Citigroup Global Markets Inc.,
c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, New York 11717, by email at
prospectus@citi.com or by telephone at 800-831-9146.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About aTyr Pharma
aTyr Pharma is engaged in the
discovery and clinical development of innovative medicines for
patients suffering from severe rare diseases using its knowledge of
Physiocrine biology, a newly discovered set of physiological
modulators. The Company's lead candidate, Resolaris™, is a
first-in-class intravenous protein therapeutic for the treatment of
rare myopathies with an immune component.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/atyr-pharma-inc-announces-closing-of-initial-public-offering-300082213.html
SOURCE aTyr Pharma, Inc.